13 November 2026 POLYCYSTIC KIDNEY DISEASE PROGRAM – ENROLMENT TARGET MET • PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available • The Company is progressing a drug candidate (known as PYC-003) that...
PKD Program - Enrolment Target Met
Filed with ASX · · 3 pages · English
Release
PYC Therapeutics Limited on 6ix
In the deck
Earlier from PYC Therapeutics
- Results of Annual General Meeting
- 2026 Annual General Meeting Program and CEO Presentation
- Notification regarding unquoted securities - PYC
- Change of Director's Interest Notice
- Annual General Meeting - Conference Link
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics